A GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition

Indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in obese adults and overweight adults with at least one weight-related comorbidity. This approval is for a new oral tablet formulation of Wegovy, making it the first orally available GLP-1 medication for obesity.

A GLP-1 receptor antagonist, this drug is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or who are overweight with at least one weight-related comorbidity. This is the first generically available GLP-1 receptor agonist for the treatment of obesity.

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity

For chronic weight management with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol) for use in addition to a reduced calorie diet and increased physical activity